Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study
Open Access
- 1 September 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Abstract
Background: As metastasis drives the majority of breast cancer-related deaths, improving outcomes for metastatic breast cancer (MBC) remains a crucial challenge. Observational studies using target trial emulation are increasingly applied to estimate treatment effects, providing insights when randomized trials are not viable. Objectives: To estimate the effect of progression-free survival (PFS) of metronomic chemotherapy of weekly paclitaxel plus cisplatin (DP) compared with treatment of the physician’s choice (TPC) for MBC. Design: This analysis was designed as a retrospective cohort study according to STROBE criteria. Methods: This retrospective cohort study compared metronomic chemotherapy of weekly DP versus TPC in MBC. The DP regimen included paclitaxel (80 mg/m 2 ) on days 1, 8, 15, 22 and cisplatin (25 mg/m 2 ) on days 1, 8, 15 in a 28-day cycle. Women aged ⩾18 years with MBC treated with at least one prior therapy between April 2014 and January 2023 at Renji Hospital were included. Propensity score matching (1:3) adjusted for confounding. The matched cohort subsequently underwent emulation of a randomized target trial, including cloning, censoring and weighting. The primary endpoint was PFS. Results: Among 313 matched patients (83 on DP, 230 on TPC), DP showed a median PFS of 13.5 months (95% CI 10.3–16.6) versus 7.9 months (95% CI: 6.7–9.1) for TPC (hazard ratio (HR) 0.77, 95% CI 0.60–0.99). Target trial emulation further improved PFS in the DP arm to 14.1 months (95% CI: 13.3–16.6) versus 8.3 months (95% CI: 8.0–8.6) for TPC (HR 0.59, 95% CI: 0.54–0.64). Subgroup analysis and sensitivity analyses confirmed result robustness. Conclusion: This study demonstrates that weekly metronomic DP chemotherapy reduces disease progression in MBC patients, particularly in first-line settings. These findings support its potential as a treatment option and warrant further study for broader application.Keywords
Funding Information
- National Natural Science Foundation of China (82103695)
- National Natural Science Foundation of China (82173115)
- Shanghai Municipal Hospital Development Center (SHDC2020CR3003A)
- Shanghai Rising-Star Program (22QC1400200)
- Renji Hospital (PYIII20-09)
- Renji Hospital (RJPY-LX-002)
- Shanghai Municipal Health Commission (202340085)
This publication has 43 references indexed in Scilit:
- Screening for Breast CancerJAMA, 2024
- Analysis of Breast Cancer Mortality in the US—1975 to 2019JAMA, 2024
- Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2-Negative Metastatic Breast CancerJAMA Oncology, 2023
- Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast CancerJAMA Oncology, 2023
- Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast CancerJAMA Network Open, 2023
- Target Trial EmulationJAMA, 2022
- Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experienceThe Breast, 2021
- Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19JAMA Internal Medicine, 2021
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialAnnals of Oncology, 2020
- Rubin, D.B.: Multiple imputation for nonresponse in surveysStatistical Papers, 1990